X4 Pharmaceuticals (XFOR) Stock Statistics & Valuation Metrics

X4 Pharmaceuticals has a market cap or net worth of $36.47M. The enterprise value is $124.90M.

X4 Pharmaceuticals has 173.66M shares outstanding. The number of shares has decreased by -2.65% in one year.

X4 Pharmaceuticals’s return on equity (ROE) is -1.69 and return on invested capital (ROIC) is -31.97%.

The current PE Ratio of X4 Pharmaceuticals is -3.94. X4 Pharmaceuticals’s PEG ratio is 0.06.

In the last 12 months, X4 Pharmaceuticals had revenue of $4.18M and earned -$16.76M in profits. Earnings per share was -$0.09.

In the last 12 months, operating cash flow was -$125.65M and capital expenditures -$320.00K, giving a free cash flow of -$125.97M billion.

X4 Pharmaceuticals pays an annual dividend of , resulting in a dividend yield of

X4 Pharmaceuticals upcoming earnings date is May 8, 2025, Before Open.

X4 Pharmaceuticals as a current ratio of 3.41, with Debt / Equity ratio of 0.12

In the past 12 months, X4 Pharmaceuticals has paid $85.00K in taxes.

X4 Pharmaceuticals EV to EBITDA ratio is -2.60, with an EV/FCF ratio of -0.72.

X4 Pharmaceuticals has $134.98M in cash and marketable securities with $78.20M in debt, giving a net cash position of -$56.77M billion.

Gross margin is 68.83%, with operating margin of -1423.58%, and net profit margin of -1464.61%.

The average price target for X4 Pharmaceuticals is $2.70, which is 11.43% higher than the current price. The consensus rating is Strong Buy